Published in Nat Rev Cancer on May 01, 2004
Graft-versus-host disease. Lancet (2009) 8.78
Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest (2008) 6.15
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood (2009) 4.98
Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit. Blood (2009) 3.05
Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood (2010) 2.45
Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood (2014) 1.92
Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells. Blood (2010) 1.88
Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res (2010) 1.84
Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7. Proc Natl Acad Sci U S A (2008) 1.77
HapMap scanning of novel human minor histocompatibility antigens. Blood (2008) 1.75
Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia. Clin Cancer Res (2009) 1.74
Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. Biol Blood Marrow Transplant (2013) 1.62
Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2012) 1.58
Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution. Blood (2011) 1.55
A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. J Clin Invest (2005) 1.33
Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited. Cancer Treat Rev (2010) 1.28
C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients. Clin Cancer Res (2008) 1.20
Immunogenicity of pluripotent stem cells and their derivatives. Circ Res (2013) 1.19
The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood (2006) 1.17
T cell receptor gene therapy for cancer. Hum Gene Ther (2009) 1.17
Mouse models of graft-versus-host disease: advances and limitations. Dis Model Mech (2011) 1.16
Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia. Immunol Cell Biol (2011) 1.14
The human leukocyte antigen-presented ligandome of B lymphocytes. Mol Cell Proteomics (2013) 1.13
Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice. J Clin Invest (2010) 1.10
Pathogenesis and management of graft-versus-host disease. Immunol Allergy Clin North Am (2010) 1.10
Effects of mismatching for minor histocompatibility antigens on clinical outcomes in HLA-matched, unrelated hematopoietic stem cell transplants. Biol Blood Marrow Transplant (2009) 1.09
NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant (2010) 1.06
Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res (2007) 1.06
Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation. Best Pract Res Clin Haematol (2008) 1.06
HDAC inhibition and graft versus host disease. Mol Med (2011) 1.02
Impact of genomic polymorphisms on the repertoire of human MHC class I-associated peptides. Nat Commun (2014) 1.01
Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses. Trends Immunol (2008) 1.01
Eicosanoid regulation of pulmonary innate immunity post-hematopoietic stem cell transplantation. Arch Immunol Ther Exp (Warsz) (2007) 0.95
Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. Cancer J (2014) 0.95
Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias. Clin Exp Immunol (2007) 0.92
Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host disease. Blood (2013) 0.91
Cell-autonomous role of TGFβ and IL-2 receptors in CD4+ and CD8+ inducible regulatory T-cell generation during GVHD. Blood (2012) 0.91
Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes. Clin Cancer Res (2010) 0.91
Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition. Proc Natl Acad Sci U S A (2009) 0.89
Adoptive T-cell therapy for B-cell malignancies. Expert Rev Hematol (2009) 0.88
PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J (2015) 0.87
Potential and limitation of HLA-based banking of human pluripotent stem cells for cell therapy. J Immunol Res (2014) 0.86
Finding a place for tumor-specific T cells in targeted cancer therapy. J Exp Med (2004) 0.85
Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation. Biol Blood Marrow Transplant (2014) 0.84
Adoptive immunotherapy against allogeneic kidney grafts in dogs with stable hematopoietic trichimerism. Biol Blood Marrow Transplant (2008) 0.84
Graft-versus-host disease: a surge of developments. PLoS Med (2007) 0.84
Polymorphisms in the base excision repair pathway and graft-versus-host disease. Leukemia (2010) 0.84
Host-derived CD8+ dendritic cells are required for induction of optimal graft-versus-tumor responses after experimental allogeneic bone marrow transplantation. Blood (2013) 0.83
T-bet is critical for the development of acute graft-versus-host disease through controlling T cell differentiation and function. J Immunol (2014) 0.82
A polymorphism in the splice donor site of ZNF419 results in the novel renal cell carcinoma-associated minor histocompatibility antigen ZAPHIR. PLoS One (2011) 0.82
Outcome of match related allogeneic stem cell transplantation procedures performed from 2004 till 2011. Exp Hematol Oncol (2012) 0.82
Immunotherapy in acute leukemia. Semin Hematol (2009) 0.82
HSPVdb--the Human Short Peptide Variation Database for improved mass spectrometry-based detection of polymorphic HLA-ligands. Immunogenetics (2010) 0.81
HapMap SNP Scanner: an online program to mine SNPs responsible for cell phenotype. Tissue Antigens (2012) 0.80
Expansion and activation kinetics of immune cells during early phase of GVHD in mouse model based on chemotherapy conditioning. Clin Dev Immunol (2010) 0.80
GVHD prevention: an ounce is better than a pound. Biol Blood Marrow Transplant (2012) 0.79
Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic). Ther Adv Hematol (2016) 0.79
Cancer vaccines: the next generation of tools to monitor the anticancer immune response. PLoS Med (2005) 0.79
siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice. Cancer Immunol Immunother (2015) 0.78
miR-146a and miR-155 Expression Levels in Acute Graft-Versus-Host Disease Incidence. Front Immunol (2016) 0.77
Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation. Expert Rev Hematol (2012) 0.77
Cancer stem cells: relevance to SCT. Bone Marrow Transplant (2009) 0.77
Ocular manifestations of graft-versus-host disease. Saudi J Ophthalmol (2013) 0.77
Rapid Recovery of CD3+CD8+ T Cells on Day 90 Predicts Superior Survival after Unmanipulated Haploidentical Blood and Marrow Transplantation. PLoS One (2016) 0.77
Both positive and negative effects on immune responses by expression of a second class II MHC molecule. Mol Immunol (2014) 0.77
Graft-versus-host disease biomarkers: omics and personalized medicine. Int J Hematol (2013) 0.77
Adoptive T-cell therapy for Leukemia. Mol Cell Ther (2014) 0.77
Toll-like receptor polymorphisms in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2014) 0.76
Two host factors regulate persistence of H7-specific T cells injected in tumor-bearing mice. PLoS One (2009) 0.76
Time to Akt: Superior tumor-reactive T cells for adoptive immunotherapy. Oncoimmunology (2015) 0.76
Novel role for surfactant protein A in gastrointestinal graft-versus-host disease. J Immunol (2012) 0.76
Structural and energetic evidence for highly peptide-specific tumor antigen targeting via allo-MHC restriction. Proc Natl Acad Sci U S A (2011) 0.75
Outcome of hematopoietic stem cell transplantation is similar for patients with a partial in vitro T-cell-depleted graft compared with a non-T-cell-depleted graft when stratified by the refined disease risk index. Bone Marrow Transplant (2016) 0.75
Deep-sequencing of the T-cell receptor repertoire in patients with haplo-cord and matched-donor transplants. Chimerism (2016) 0.75
Conditional control of suicide gene expression in tumor cells with theophylline responsive ribozyme. Gene Ther (2016) 0.75
Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I. Clin Pharmacokinet (2016) 0.75
Genetic barriers in transplantation medicine. World J Transplant (2016) 0.75
HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. J Transl Med (2017) 0.75
Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy. Haematologica (2016) 0.75
Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease. PLoS One (2016) 0.75
Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia. Core Evid (2005) 0.75
Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock? Target Oncol (2017) 0.75
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood (2008) 7.01
Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood (2009) 7.00
Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest (2008) 6.15
Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit. Blood (2009) 3.05
Overlap and effective size of the human CD8+ T cell receptor repertoire. Sci Transl Med (2010) 3.01
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood (2012) 2.97
A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy. Immunity (2009) 2.64
Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood (2010) 2.61
The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood (2010) 2.59
Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood (2002) 2.48
Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood (2010) 2.45
CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood (2013) 2.22
Redox regulation facilitates optimal peptide selection by MHC class I during antigen processing. Cell (2006) 2.20
An antigen produced by splicing of noncontiguous peptides in the reverse order. Science (2006) 2.18
A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood (2011) 2.15
Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood (2009) 2.00
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood (2003) 1.93
CD27 expression promotes long-term survival of functional effector-memory CD8+ cytotoxic T lymphocytes in HIV-infected patients. J Exp Med (2004) 1.92
Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells. Blood (2010) 1.88
Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res (2013) 1.85
Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus. J Clin Invest (2002) 1.79
CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest (2016) 1.75
HapMap scanning of novel human minor histocompatibility antigens. Blood (2008) 1.75
Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia. Clin Cancer Res (2009) 1.74
Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Hum Gene Ther (2007) 1.70
Induction of cytotoxic T-lymphocyte responses to enhanced green and yellow fluorescent proteins after myeloablative conditioning. Blood (2003) 1.61
A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med (2003) 1.61
Restoration of CD28 expression in CD28- CD8+ memory effector T cells reconstitutes antigen-induced IL-2 production. J Exp Med (2003) 1.55
Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. Blood (2011) 1.54
Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale. J Immunother (2012) 1.47
Human cytomegalovirus microRNA miR-US4-1 inhibits CD8(+) T cell responses by targeting the aminopeptidase ERAP1. Nat Immunol (2011) 1.46
Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin Cancer Res (2004) 1.42
Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8+ cytotoxic T-cell response in natural infection. Blood (2004) 1.42
Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells. Cancer Res (2009) 1.37
Adoptive transfer of virus-specific and tumor-specific T cell immunity. Curr Opin Immunol (2009) 1.36
Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc Natl Acad Sci U S A (2005) 1.36
Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev (2014) 1.33
Highly efficient gene transfer into baboon marrow repopulating cells using GALV-pseudotype oncoretroviral vectors produced by human packaging cells. Blood (2002) 1.24
Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein. J Immunol (2003) 1.21
C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients. Clin Cancer Res (2008) 1.20
HLA engineering of human pluripotent stem cells. Mol Ther (2013) 1.19
Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus. J Exp Med (2009) 1.19
Enhanced transgene expression in quiescent and activated human CD8+ T cells. Hum Gene Ther (2004) 1.19
The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood (2006) 1.17
Innate signals overcome acquired TCR signaling pathway regulation and govern the fate of human CD161(hi) CD8α⁺ semi-invariant T cells. Blood (2011) 1.16
Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia. Immunol Cell Biol (2011) 1.14
Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts. J Clin Invest (2015) 1.13
Engineered T cells for anti-cancer therapy. Curr Opin Immunol (2012) 1.12
Immune responses to AAV in canine muscle monitored by cellular assays and noninvasive imaging. Mol Ther (2009) 1.11
Generation of HIV-1-specific CD8+ cell responses following allogeneic hematopoietic cell transplantation. Blood (2008) 1.10
National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. Biol Blood Marrow Transplant (2011) 1.09
Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. Blood (2003) 1.06
Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo. Blood (2013) 1.06
Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy. Curr Opin Immunol (2011) 1.04
TCR-ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer. Sci Transl Med (2013) 1.02
DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells. Blood (2008) 1.01
A UGT2B17-positive donor is a risk factor for higher transplant-related mortality and lower survival after bone marrow transplantation. Br J Haematol (2005) 1.00
Artificial antigen-presenting cells for use in adoptive immunotherapy. Cancer J (2010) 1.00
Association between immune recovery uveitis and a diverse intraocular cytomegalovirus-specific cytotoxic T cell response. J Infect Dis (2002) 0.99
Novel serial positive enrichment technology enables clinical multiparameter cell sorting. PLoS One (2012) 0.98
Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant (2010) 0.96
Cytomegalovirus viral load and virus-specific immune reconstitution after peripheral blood stem cell versus bone marrow transplantation. Biol Blood Marrow Transplant (2011) 0.95
Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling. Br J Haematol (2003) 0.95
Recognition of breast cancer cells by CD8+ cytotoxic T-cell clones specific for NY-BR-1. Cancer Res (2006) 0.93
HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathway. J Immunol (2013) 0.92
CD28 costimulation and immunoaffinity-based selection efficiently generate primary gene-modified T cells for adoptive immunotherapy. Blood (2002) 0.92
A single minor histocompatibility antigen encoded by UGT2B17 and presented by human leukocyte antigen-A*2902 and -B*4403. Transplantation (2007) 0.91
Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma. Cancer Immunol Immunother (2011) 0.91
Adoptive T-cell therapy for B-cell malignancies. Expert Rev Hematol (2009) 0.88
Cytomegalovirus disease before hematopoietic cell transplantation as a risk for complications after transplantation. Biol Blood Marrow Transplant (2005) 0.84
Targeted cloning of cytotoxic T cells specific for minor histocompatibility antigens restricted by HLA class I molecules of interest. Transplantation (2002) 0.82
Double unit cord blood transplantation: Who wins-and why do we care? Chimerism (2016) 0.80
Proliferation-linked apoptosis of adoptively transferred T cells after IL-15 administration in macaques. PLoS One (2013) 0.80
HIV-1 Vpr does not inhibit CTL-mediated apoptosis of HIV-1 infected cells. Virology (2002) 0.79
Immunologic predictors of late cytomegalovirus disease after solid organ transplantation--an elusive goal? J Infect Dis (2007) 0.79
Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation. Expert Rev Hematol (2012) 0.77
Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. J Clin Invest (2016) 0.75
Genetic modification of T cells for immunotherapy. Expert Opin Biol Ther (2007) 0.75